The chemopreventive effects of Ibuprofen on the development and growth of 7,12-dimethylbenz(a)anthracene (DMBA) induced rat mammary tumors were examined. A well known breast cancer chemopreventive retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR) was also included in this study for comparison. At 7 days prior to receiving a single intragastric dose of 15 mg DMBA, rats were fed a control chow diet, as well as diets containing either 1000 mg/kg diet of Ibuprofen or 1.5 mmol/kg diet of 4-HPR. Ibuprofen and 4-HPR markedly increased tumor latency. At 112 days post DMBA intubation, tumor incidence was 86% in control rats as compared to 74% and 62% in rats receiving Ibuprofen, and 4-HPR diets respectively (p < 0.05). Ibuprofen and 4-HPR reduced tumor burden and tumor volume almost to the same extent. The control rats had an average of 2.26 tumors/rat compared to 1.42 and 1.46 tumors/rat in the Ibuprofen or 4-HPR groups respectively (p < 0.05). Similarly, average tumor volume was 3.25 cm3 in the control rats compared to 0.86 cm3 and 0.83 cm3 in rats receiving Ibuprofen and 4-HPR diets respectively (p < 0.05). These results suggest that Ibuprofen may have potential in the chemoprevention and treatment of breast cancer.

Download full-text PDF

Source

Publication Analysis

Top Keywords

ibuprofen 4-hpr
20
control rats
12
ibuprofen
9
n-4-hydroxyphenyl retinamide
8
development growth
8
rat mammary
8
breast cancer
8
rats compared
8
rats receiving
8
receiving ibuprofen
8

Similar Publications

Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.

Cochrane Database Syst Rev

September 2019

Department of Pediatrics, Montreal Children's Hospital, 2300 Tupper Street, Montreal, QC, Canada, H3H 1PA.

Background: Progressive lung damage causes most deaths in cystic fibrosis. Non-steroidal anti-inflammatory drugs (such as ibuprofen) may prevent progressive pulmonary deterioration and morbidity in cystic fibrosis. This is an update of a previously published review.

View Article and Find Full Text PDF

Comparative toxicity was determined for twenty potential chemopreventive agents in the Human Epithelial Cell Cytotoxicity (HECC) Assay using epithelial cell cultures from eight different tissues including: skin, kidney, breast, bronchus, cervix, prostate, oral cavity, and liver. The endpoints assessed were inhibition of: growth at 3 and 5 days; mitochondrial function; and proliferating cell nuclear antigen or albumin expression. Difluoromethylornithine (DFMO), s-allylcysteine, dehydroepiandrosterone (DHEA) analogue 8543, l-selenomethionine, and vitamin E acetate were not toxic or only produced mild toxicity with all endpoints in all eight cell types.

View Article and Find Full Text PDF

A rodent model of carcinogen-induced mammary tumorigenesis was used to determine the comparative growth inhibitory effects of dietary administration of either 1000 mg/kg of the non-steroidal antiinflammatory drug (NSAID) ibuprofen or 1.5 mmol/kg of the synthetic retinoid N-(4-hydroxyphenyl)-retinamide (4-HPR). In addition, the effects of these compounds on gene expression and protein production of the two isoforms of the cyclooxygenase (COX) gene which are responsible for prostaglandin production were examined.

View Article and Find Full Text PDF

The chemopreventive effects of Ibuprofen on the development and growth of 7,12-dimethylbenz(a)anthracene (DMBA) induced rat mammary tumors were examined. A well known breast cancer chemopreventive retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR) was also included in this study for comparison. At 7 days prior to receiving a single intragastric dose of 15 mg DMBA, rats were fed a control chow diet, as well as diets containing either 1000 mg/kg diet of Ibuprofen or 1.

View Article and Find Full Text PDF

New agents for cancer chemoprevention.

J Cell Biochem Suppl

July 1997

Chemoprevention Branch, National Cancer Institute (NCI), Bethesda, MD 20892, USA.

Clinical chemoprevention trials of more than 30 agents and agent combinations are now in progress or being planned. The most advanced agents are well known and are in large Phase III chemoprevention intervention trials or epidemiological studies. These drugs include several retinoids [e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!